Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cardiol Therapeutics (CRDL)

Cardiol Therapeutics (CRDL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 154,307
  • Shares Outstanding, K 111,817
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,200 K
  • EBIT $ -25 M
  • EBITDA $ -24 M
  • 60-Month Beta 0.82
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 12.05

Options Overview Details

View History
  • Implied Volatility 242.11% (+37.94%)
  • Historical Volatility 73.87%
  • IV Percentile 25%
  • IV Rank 17.59%
  • IV High 1,171.62% on 10/14/25
  • IV Low 43.77% on 03/16/26
  • Expected Move (DTE 5) 1.0370 (75.14%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 125
  • Volume Avg (30-Day) 75
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 4,016
  • Open Int (30-Day) 8,104
  • Expected Range 0.3430 to 2.4170

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.06
  • Number of Estimates 2
  • High Estimate $-0.06
  • Low Estimate $-0.07
  • Prior Year $-0.07
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8974 +53.78%
on 03/20/26
1.4800 -6.76%
on 04/02/26
+0.3200 (+30.19%)
since 03/10/26
3-Month
0.8974 +53.78%
on 03/20/26
1.4800 -6.76%
on 04/02/26
+0.3827 (+38.37%)
since 01/09/26
52-Week
0.8727 +58.13%
on 04/11/25
1.5900 -13.21%
on 07/28/25
+0.4840 (+54.02%)
since 04/10/25

Most Recent Stories

More News
Cardiol Therapeutics Announces Year-End 2025 Update on Operations

Initiated pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis and surpassed 50% patient enrollment, with full enrollment expected in Q2 2026.Reported positive Phase II ARCHER data...

CRDL.TO : 1.93 (+2.66%)
CRDL : 1.3800 (unch)
Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference

Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development...

CRDL.TO : 1.93 (+2.66%)
CRDL : 1.3800 (unch)
Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure

Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development...

CRDL.TO : 1.93 (+2.66%)
CRDL : 1.3800 (unch)
Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million

Toronto, Ontario--(Newsfile Corp. - January 23, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development...

CRDL.TO : 1.93 (+2.66%)
CRDL : 1.3800 (unch)
Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million

Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development...

CRDL.TO : 1.93 (+2.66%)
CRDL : 1.3800 (unch)
Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers actively enrolling patients.Activation of additional top-tier clinical sites in Europe and Canada...

CRDL.TO : 1.93 (+2.66%)
CRDL : 1.3800 (unch)
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

(December 1, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company advancing anti-inflammatory and

CRDL.TO : 1.93 (+2.66%)
CRDL : 1.3800 (unch)
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with acute...

CRDL.TO : 1.93 (+2.66%)
CRDL : 1.3800 (unch)
Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040

Once issued, this new U.S. patent covers the use of CardiolRx™ and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual property...

CRDL.TO : 1.93 (+2.66%)
CRDL : 1.3800 (unch)
Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases

The ESC M&PD meeting brings together the world's experts working to improve the treatment of myocarditis and pericarditis.Presentation to provide comprehensive findings from the ARCHER trial following...

CRDL.TO : 1.93 (+2.66%)
CRDL : 1.3800 (unch)

Business Summary

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease. The company's lead product consist CardiolRx(TM). Cardiol Therapeutics Inc. is based in Oakville, ON.

See More

Key Turning Points

3rd Resistance Point 1.4933
2nd Resistance Point 1.4667
1st Resistance Point 1.4233
Last Price 1.3800
1st Support Level 1.3533
2nd Support Level 1.3267
3rd Support Level 1.2833

See More

52-Week High 1.5900
Last Price 1.3800
Fibonacci 61.8% 1.3160
Fibonacci 50% 1.2313
Fibonacci 38.2% 1.1467
52-Week Low 0.8727

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.